Yuanquan Yang
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Summary of treatment de-escalation. Overview of dose de-escalation, number ( n ) of patients at each level, and number of patients experiencing a DLT at each dose level. bid, twice daily; D, day; IV, intravenously; PO, orally; qd, once a day.
Year:
2025
Elimusertib concentrations by toxicity. DLT occurrence and week 1 cumulative elimusertib based on day 2 AUC 0–12 hours by cisplatin dose. Open circles, individual patients; solid dash, geometric mean.
Year:
2025
Purpose: The ataxia telangiectasia and Rad3–related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin. Patients and Methods: Patients with advanced solid tumors who had received 2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m 2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy. Results: Fifteen patients were enrolled. Dose level −2 (elimusertib 20 mg once on day 2 and cisplatin 30 mg/m 2 on days 1 and 8) was deemed the maximum tolerated dose; dose-limiting toxicities (DLT) including creatinine increase, hypokalemia, febrile neutropenia, neutropenia, syncope, and thrombocytopenia, required dose de-escalation. Although the four patients with the highest elimusertib exposure all experienced hematologic DLTs within 1 week, they also received a higher day 1 cisplatin dose, precluding a definitive association of elimusertib exposure with DLT occurrence. Of 10 evaluable patients, one (10%) with clear-cell ovarian cancer had a partial response, whereas five (50%) had stable disease. Conclusions: Cisplatin combined with elimusertib was associated with hematologic toxicity requiring significant dose de-escalation. Elimusertib pharmacokinetics was consistent with prior studies. Only modest activity was observed. Further clinical evaluation of elimusertib plus cisplatin is not warranted. Significance: Preclinical data suggest synergy between cisplatin and the ataxia telangiectasia and Rad3–related inhibitor elimusertib, leading to this phase Ib trial in advanced solid tumors evaluating feasibility. The results do not support further examination of the combination due to DLTs observed in the absence of robust efficacy.
Year:
2025
Year:
2023
Collaborators (8)
Paul Frankel
Research Professor
Beckman Research Institute, City of Hope
Arjun Mittra
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Jan Beumer
Professor (PAR)
Johns Hopkins University
Ming Yin
Assistant Professor
The Ohio State University Wexner Medical Center
Anne Noonan
Professor
The Ohio State University Comprehensive Cancer Center
Philippe L. Bedard
University Health Network
Nataliya Uboha
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.